|
| |
Localized delivery of PDE-4
inhibitors to open the therapeutic window
The
Localized delivery of
phosphodiesterase-4 (PDE-4)
inhibitors appears to be short term solution to overcome
the dose-limiting side effects of severe nausea and emesis occurring after oral
administration. In the long-term, subtype-selective PDE-4 inhibitors and
combination regimens may help to improve the therapeutic index..
Barcelona, Spain | May 30, 2006 | The Business Intelligence
firm La Merie S.L. reported today that application of PDE-4 inhibitors as
inhaled treatment for bronchial asthma and chronic obstructive pulmonary disease
(COPD) or as nasal suspension for the treatment of allergic rhinitis are
increasingly used clinical options to avoid dose-limiting side effects of severe
nausea and vomiting seen with oral administration. Furthermore, topical
administration of
PDE-4 inhibitors is
evaluated in atopic dermatitis and allergic conjunctivitis. Further clinical
uses of PDE-4 inhibitors are inflammatory diseases such as rheumatoid arthritis
and ulcerative colitis apart from memory disorders such as Alzheimer's disease.
These results and more were found in a competitor analysis conducted by La Merie
Business Intelligence. The findings of the search can be acquired at
www.pipelinereview.com ,
La Merie 's News Center and Online Store.
Most of the orally delivered PDE-4 inhibitors to treat asthma and COPD did not
make it beyond phase II clinical studies. The major challenge is a narrow
therapeutic index caused by dose-limiting side effects, including severe nausea
and emesis. The two PDE-4 inhibitors which reached the registration phase were
either withdrawn from the MAA process (roflumilast) or received an approvable
letter requesting additional confirmatory trial data. The interest in
PDE-4 inhibitors still is
high as reflected by at least five ongoing development projects in pulmonary &
respiratory diseases. The anti-inflammatory properties of PDE-4 inhibitors are
also evaluated in atopic dermatitis, allergic conjunctivitis, rheumatoid
arthritis and ulcerative colitis. Several companies are specifically searching
for PDE-4 inhibitors in memory disorders and ischemic stroke.
Non-selective
PDE-4 inhibitors , multi-PDE
inhibitors and dual M3/PDE-4 blockers are also evaluated in a variety of
inflammatory indications including multiple sclerosis, psoriasis, COPD/asthma
and cystitis. Most of the inhibitors are small molecules, but antisense may be
used for inhalation treatment.
About R&D Pipeline News
R&D Pipeline News is a premier information source about research and
development projects in the pipeline of the biopharmaceutical industry. The
periodical is directed to all stakeholders in R&D. The weekly publication comes
in a rapid- and easy-to-screen tabular format and provides access to the
original information source via hyperlinks. R&D Pipeline News covers all
relevant treatment modalities and is directly delivered to the desktop via
e-mail. More information about the journal, a free trial and subscriptions are
available via La Merie’s Business Intelligence Center
www.pipelinereview.com .
About La Merie
La Merie S.L. is a Business Intelligence enterprise fully dedicated to provide
high quality R&D information to the biopharmaceutical industry. La Merie offers
individual consultancy services and publishes reports and periodicals.
They publish two weekly
newsletters - apply for a FREE three week trial:
R&D Pipeline News is a premier
information source about research and development projects in the pipeline of
the biopharmaceutical industry and is directed to all stakeholders in R&D. The
weekly publication comes in a rapid- and easy-to-screen tabular format and
provides access to the original information source via hyperlinks. R&D Pipeline
News covers all relevant treatment modalities and is directly delivered to the
desktop via e-mail.
| |
|
